Rodrigues, Manuel http://orcid.org/0000-0002-5443-0802
Vanoni, Giulia
Loap, Pierre
Dubot, Coraline
Timperi, Eleonora http://orcid.org/0000-0002-8357-6587
Minsat, Mathieu
Bazire, Louis
Durdux, Catherine
Fourchotte, Virginie
Laas, Enora
Pouget, Nicolas
Castel-Ajgal, Zahra
Marret, Gregoire
Lesage, Laetitia http://orcid.org/0000-0001-8592-2482
Meseure, Didier http://orcid.org/0000-0001-6730-6686
Vincent-Salomon, Anne http://orcid.org/0000-0001-5754-5771
Lecompte, Lolita http://orcid.org/0000-0001-8773-6317
Servant, Nicolas http://orcid.org/0000-0003-1678-7410
Vacher, Sophie http://orcid.org/0000-0002-0042-6023
Bieche, Ivan
Malhaire, Caroline http://orcid.org/0000-0002-9235-9816
Huchet, Virginie
Champion, Laurence http://orcid.org/0000-0001-7908-5593
Kamal, Maud
Amigorena, Sebastian http://orcid.org/0000-0001-8583-8416
Lantz, Olivier http://orcid.org/0000-0003-3161-7719
Chevrier, Marion
Romano, Emanuela http://orcid.org/0000-0002-1574-5545
Funding for this research was provided by:
AstraZeneca
Bristol-Myers Squibb
Article History
Received: 6 January 2023
Accepted: 12 June 2023
First Online: 22 June 2023
Competing interests
: M.R. reports personal fees for serving as an advisor from Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Immunocore; travel support from AstraZeneca; funds to his institution to support a study from Merck Sharp & Dohme. E.R. reports investigator-initiated trial funds (paid to the institution) by AstraZeneca, BMS, and Replimune; serves on the consultancy/advisory board for AstraZeneca, Merck, Roche, Light Chain Biosciences, Pierre Fabre; E.R. declares travel support from BMS, Hoffmann La Roche, AstraZeneca, Merck Sharp & Dohme. G.V. and E.R. received grants from the Fonds Amgen France pour la Science et l’Humain. MR and ER report funding to their institution to support a study from Janssen-Cilag. CaD received grants from AstraZeneca, Janssen, and Astellas. M.K. received funds from Roche. The remaining co-authors declare no competing interests.